Syros Pharmaceuticals Q2 2024 GAAP EPS $(0.59) Beats $(0.79) Estimate
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.59), which beats the estimated $(0.79).
July 31, 2024 | 10:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syros Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.59), beating the estimated $(0.79). This positive earnings surprise is likely to boost investor confidence and could lead to a short-term increase in the stock price.
The better-than-expected earnings per share (EPS) indicates that the company is performing better than analysts anticipated. This positive surprise is likely to increase investor confidence and could result in a short-term price increase for SYRS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100